Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab/tuvonralimab plus FOLFOXIRI and targeted therapy in extensive-stage MSS metastatic colorectal cancer
ChiCTR2600132796Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Oct 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ipilimumab, tuvonralimab, cetuximab, bevacizumab, fluorouracil and 3 more in colorectal cancer (CRC), colorectal adenocarcinoma, metastatic colorectal adenocarcinoma (mCRC) and 1 more, sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoints: Maximum tolerated dose and recommended phase II dose, Incidence and characteristics of dose-limiting toxicities and 1 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
ipilimumabtuvonralimabcetuximabbevacizumabfluorouracil
03
Conditions
colorectal cancer (CRC)colorectal adenocarcinomametastatic colorectal adenocarcinoma (mCRC)microsatellite stable colorectal cancer
Beyond the preview
Go deeper on ChiCTR2600132796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132796.